News|Articles|December 2, 2013

Aptuit Appoints New CEO

Aptuit appoints Jonathan Goldman as CEO.

Aptuit, a provider of outsourced services in the early development space, has appointed Jonathan Goldman, MD, as the company’s new CEO. Goldman joins the company after working at ICON Clinical Research.

Goldman was most recently executive vice president, global strategic and business development at ICON and a member of the senior leadership team. Previously, his roles at ICON included executive VP, operations, strategic programs and chief medical officer, ICON Medical Imaging.

Before joining ICON, Goldman served for seven years as the chief medical officer of POINT Biomedical, a US-based biopharmaceutical company that discovered and developed microsphere technologies and drugs. In addition, he has held academic positions at the University of California since 2000, most recently as associate clinical professor of medicine in the Division of Cardiology.

Source: Aptuit


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.